AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 75 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2018. The put-call ratio across all filers is 1.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $11,325,000 | +44.0% | 2,722,241 | 0.0% | 0.46% | +63.3% |
| Q2 2019 | $7,867,000 | +100.7% | 2,722,241 | 0.0% | 0.28% | +88.7% |
| Q1 2019 | $3,920,000 | -44.2% | 2,722,241 | 0.0% | 0.15% | -46.6% |
| Q4 2018 | $7,023,000 | -41.2% | 2,722,241 | 0.0% | 0.28% | -34.3% |
| Q3 2018 | $11,951,000 | -28.4% | 2,722,241 | 0.0% | 0.43% | -27.0% |
| Q2 2018 | $16,687,000 | -39.6% | 2,722,241 | -28.1% | 0.59% | -38.8% |
| Q1 2018 | $27,618,000 | -14.9% | 3,788,540 | -4.2% | 0.96% | -25.1% |
| Q4 2017 | $32,435,000 | -15.5% | 3,955,494 | +8.2% | 1.28% | -26.1% |
| Q3 2017 | $38,383,000 | -4.8% | 3,655,494 | 0.0% | 1.73% | -19.6% |
| Q2 2017 | $40,320,000 | +2.3% | 3,655,494 | -10.2% | 2.15% | +41.4% |
| Q1 2017 | $39,425,000 | – | 4,072,809 | – | 1.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |